Diagnosis and treatment of acute lymphatic leukemia in adults [Diagnostik und therapie der akuten lymphatischen leukämie des erwachsenen]

Annino L., Vegna M.L., Camera A., Et al., Treatment of adult acute lymphoblastic leukemia (ALL) (2002) long-term follow-up of the GIMEMA ALL 0288 randomized study, Blood, 99, pp. 863-871

Asselin B.L., The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia, Adv Exp Med Biol, 457, pp. 621-629, (1999)

Brueggemann M., Droese J., Raff Th., Et al., The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia, Blood, 98, (2001)

Brueggemann M., Droese J., Scheuring U., Et al., Minimal residual disease in adult patients with acute lymphoblastic leukemia during the first year of therapy predicts clinical outcome, Hematol J, 1, SUPPL. 1, (2001)

Campana D., Pui C.H., Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance, Blood, 85, pp. 1416-1434, (1995)

Cave H., Van der Werff Ten Bosch J., Suciu S., Et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia, N Engl J Med, 339, pp. 591-598, (1998)

Cornelissen J.J., Carston M., Kollman C., Et al., Unrelated marrow transplantation for adult patients with poor-risk acute lympho blastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome, Blood, 97, pp. 1572-1577, (2001)

Coustan-Smith E., Sancho J., Hancock M.L., Et al., Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, 96, pp. 2691-2696, (2000)

Durrant I.J., Prentice H.G., Richards S.M., Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research council randomized trial UKALL XA, Br J Haematol, 99, pp. 84-92, (1997)

Duval M., Suciu S., Ferster A., Et al., Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial, Blood, 99, pp. 2734-2739, (2002)

Annino L., Vegna M.L., Camera A., Et al., Treatment of adult acute lymphoblastic leukemia (ALL) (2002) long-term follow-up of the GIMEMA ALL 0288 randomized study, Blood, 99, pp. 863-871

Asselin B.L., The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia, Adv Exp Med Biol, 457, pp. 621-629, (1999)

Brueggemann M., Droese J., Raff Th., Et al., The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia, Blood, 98, (2001)

Brueggemann M., Droese J., Scheuring U., Et al., Minimal residual disease in adult patients with acute lymphoblastic leukemia during the first year of therapy predicts clinical outcome, Hematol J, 1, SUPPL. 1, (2001)

Campana D., Pui C.H., Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance, Blood, 85, pp. 1416-1434, (1995)

Cave H., Van der Werff Ten Bosch J., Suciu S., Et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia, N Engl J Med, 339, pp. 591-598, (1998)

Cornelissen J.J., Carston M., Kollman C., Et al., Unrelated marrow transplantation for adult patients with poor-risk acute lympho blastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome, Blood, 97, pp. 1572-1577, (2001)

Coustan-Smith E., Sancho J., Hancock M.L., Et al., Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, 96, pp. 2691-2696, (2000)

Durrant I.J., Prentice H.G., Richards S.M., Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research council randomized trial UKALL XA, Br J Haematol, 99, pp. 84-92, (1997)

Duval M., Suciu S., Ferster A., Et al., Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial, Blood, 99, pp. 2734-2739, (2002)